Adia Med to Expand Treatment Offerings with Therapeutic Plasma Exchange (TPE) Across All Future Full Clinic Locations
Rhea-AI Summary
Adia Nutrition (OTC: ADIA) has announced that its subsidiary, Adia Med, will incorporate Therapeutic Plasma Exchange (TPE) treatment across all future full clinic locations in the United States, with its current location already offering this service. TPE uses apheresis machines to remove and replace patient plasma, targeting harmful substances in the bloodstream.
The clinics will utilize the same equipment used for Hematopoietic Stem Cell Transplantation (HSCT), making Adia Med one of only three clinic networks in the U.S. with this technology. The treatment shows promise for various conditions, including Alzheimer's disease, where studies indicate TPE combined with albumin replacement can slow cognitive decline.
The national average cost for TPE ranges from $4,000 to $6,000 per patient. With Florida's large retiree population of over 4.5 million residents aged 65 and older, Adia Med sees significant market potential, particularly for age-related conditions and autoimmune disorders.
Positive
- Current clinic already generating revenue from TPE treatments
- One of only three clinic networks in U.S. with this specialized technology
- Large target market with 4.5M Florida residents aged 65+
- TPE treatment costs of $4,000-$6,000 per patient indicate strong revenue potential
- Insurance coverage already approved for some Alzheimer's applications
Negative
- Significant competition from two other clinic networks with similar technology
- High treatment costs may limit accessibility for uninsured patients
- Success depends on expansion to new clinic locations not yet established
News Market Reaction – ADIA
In the trading session that priced this news, ADIA declined 11.00%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Winter Park, Florida--(Newsfile Corp. - March 17, 2025) - Adia Nutrition (OTC Pink: ADIA), a leader in innovative healthcare solutions, is thrilled to announce that its subsidiary, Adia Med, will ensure that all future full clinic locations across the United States will offer Therapeutic Plasma Exchange (TPE), with its current location already offering this advanced treatment as of today. These full clinics, which will also perform Hematopoietic Stem Cell Transplantation (HSCT) for various conditions using state-of-the-art apheresis machines, will integrate TPE into their offerings, leveraging the same cutting-edge equipment. This forward-thinking expansion will unlock a wide range of applications, including potential benefits for Alzheimer's disease, reinforcing Adia Med's commitment to pioneering patient care.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/243472_70824-9959585.jpeg
TPE, a procedure that utilizes an apheresis machine to remove and replace a patient's plasma, will target harmful substances—such as autoantibodies, immune complexes, and toxins—in the bloodstream, offering hope for numerous conditions, including neurodegenerative diseases like Alzheimer's. With all future Adia Med full clinics set to utilize apheresis technology for HSCT, they will seamlessly adopt TPE, maximizing the potential of this sophisticated equipment. The current Adia Med location, now offering TPE, marks the first step in this transformative vision.
"We are excited to announce that all our future full clinics will provide TPE, a treatment with immense potential to change lives, including for those affected by Alzheimer's," said Larry Powalisz, CEO of Adia Med. "Our current location is already delivering this therapy, and as we grow, every new full clinic equipped with top-tier apheresis machines will expand access to this innovative care. As one of just three clinic networks in the U.S. with this technology, we will continue to lead the charge in advanced medical solutions."
Studies have highlighted the promising benefits and versatility of TPE across various conditions, including Alzheimer's disease. A study published in Alzheimer's & Dementia explored the AMBAR trial, which showed that TPE combined with albumin replacement slowed cognitive and functional decline in patients with mild-to-moderate Alzheimer's, suggesting that removing amyloid-beta proteins and other toxic plasma components could play a key role in disease management. Notably, insurance has already covered TPE for Alzheimer's applications in some cases, reflecting growing recognition of its potential.
Additionally, research in Transfusion and Apheresis Science demonstrated TPE's ability to reduce mortality in moderate-to-critical COVID-19 patients, with a risk ratio of 0.41 (
The national average cost for TPE ranges from
Patients and healthcare providers eager to explore TPE and other services at Adia Med's clinics can visit www.adiamed.com or contact 321-788-0850 for more information as these offerings roll out.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/243472